PHAXIAM develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to severe infections.
The phages (or bacteriophages) are harmless to human organisms and specifically eradicate bacteria in an ultra-targeted way to fight microbial infections. They offer excellent efficacy against bacteria – including bacteria that are multi-resistant to antibiotics –, are very well tolerated due to their high specificity and adapt very quickly to bacterial mutations while respecting microbiota, unlike antibiotics.
Pherecydes Pharma has introduced the concept of precision phagotherapy, which consists in treating each patient according to the activity of the phages on the strain responsible for the infection. Treatments are therefore individualized and adapted to each case.
Our team has selected as priority targets three families of bacteria listed by the WHO as being among the most dangerous: Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. These three bacterial infections alone account for over 2/3 of hospital acquired hospital acquired infections in industrialized countries.
Discover